Integra LifeSciences Holdings Corporation
NASDAQ:IARTMedical - Devices
+$0.81 today
- Market cap
- $1.08B
- Beta
- 1.25
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$6.44
Volume 0.58M
Average 0.96M
IART Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Integra LifeSciences Holdings CorporationNASDAQ: IART
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow dips below year-ago levels
Q1 FY2026 financing cash flow of $8.3M fell 76.5% year over year, behind the +101.5% change in trailing-twelve-month financing cash flow. Sequentially, it fell 65.9% from the prior quarter.
Context
- Financing cash flow amounted to 1.7% of revenue in FY2025, down 13.0 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -76.5% toward the trailing-twelve-month pace of +101.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 28.34M USD
- Year-over-year change
- -88.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.34M | -88.1% |
| FY2024 | 2024-12-31 | 237.86M | +203.5% |
| FY2023 | 2023-12-31 | (229.93M) | +8.7% |
| FY2022 | 2022-12-31 | (251.95M) | -156.5% |
| FY2021 | 2021-12-31 | (98.23M) | — |
Financing Cash Flow vs competitors
How IART compares with its peers on the latest reported figures
- IART's LTM Mar 2026 financing cash flow of $1.26M is the smallest of the 11 companies compared; the peer median is $12.22M.
- Its year-over-year change of +101.5% is the 4th highest of 11, against a peer median of -30.2%.
- Financing cash flow amounts to 0.1% of revenue for IART, versus a peer median of 10.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $3.04B | -226.3% | — | 11.8% | |
| FY2025 | $955M | +1010.5% | +1.0% | 15.5% | |
| LTM Sep 2026 | $293.55M | +4152.5% | +80.2% | 110.0% | |
| LTM Jun 2026 | $135.13M | -76.7% | +83.5% | 4.3% | |
| LTM Mar 2026 | $129.98M | -20.0% | — | 9.5% | |
| LTM Mar 2026 | $63.96M | +123.6% | +116.0% | 7.7% | |
| LTM Jun 2026 | $25.56M | -40.4% | -14.3% | 32.0% | |
| LTM Mar 2026 | $21.93M | -319.8% | — | 18.0% | |
| LTM Mar 2026 | $9.56M | +76.9% | — | 2.1% | |
| LTM Mar 2026 | $2.52M | -102.8% | -1.3% | 0.3% | |
| LTM Mar 2026 | $1.26M | +101.5% | — | 0.1% | |
| Peer median (excluding IART) | $12.22M | -30.2% | +40.6% | 10.6% | |
Competitors are the stored peer set for IART. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 169.08M | 180.55M | 67.74M | (6.94M) | (516.47M) |
| Depreciation & Amortization | 119.84M | 118.3M | 123.51M | 140.89M | 151.83M |
| Deferred Income Tax | (2.76M) | (4.59M) | (11.89M) | (20.73M) | (66.26M) |
| Stock-Based Compensation | 36.21M | 27.73M | 20.14M | 24.38M | 18.58M |
| Change in Working Capital | 18.16M | (39.42M) | (81.57M) | (31.01M) | (33.74M) |
| Accounts Receivables | 7.27M | (33.91M) | 4.59M | 7.4M | (485K) |
| Inventory | 5.37M | (29.12M) | (59.77M) | (28.15M) | (46.76M) |
| Accounts Payables | 32.87M | 17.34M | (20.23M) | (2.67M) | 26.72M |
| Other Working Capital | (27.35M) | 6.27M | (6.17M) | (7.58M) | (13.22M) |
| Other Non-Cash Items | (28.1M) | (18.1M) | 22.02M | 22.79M | 496.44M |
| Operating Cash Flow | 312.43M | 264.47M | 139.96M | 129.38M | 50.38M |
| Capital Expenditures | (48.08M) | (47.09M) | (66.87M) | (104.42M) | (95.64M) |
| Acquisitions (Net) | (113.44M) | (27.55M) | 0 | (277.81M) | 0 |
| Purchases of Investments | 0 | (4.91M) | (32.69M) | (49M) | (19.43M) |
| Sales of Investments | 76K | 4.91M | 5.38M | 54.5M | 7M |
| Other Investing Activities | (55K) | 16.05M | 0 | (14.08M) | (14.2M) |
| Investing Cash Flow | (161.44M) | (58.58M) | (94.18M) | (390.81M) | (108.06M) |
| Debt Repayment | (100M) | (107.8M) | 54.5M | 299.37M | 46.75M |
| Common Stock Issued | 6.82M | 0 | 0 | 0 | 957K |
| Common Stock Repurchased | 0 | (125M) | (275M) | (52.47M) | (221K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (5.05M) | (24.62M) | (9.43M) | (9.04M) | (19.15M) |
| Financing Cash Flow | (98.23M) | (251.95M) | (229.93M) | 237.86M | 28.34M |
| Effect of Forex Changes | (9.48M) | (10.72M) | 3.89M | (6.46M) | 18.02M |
| Net Change in Cash | 43.28M | (56.79M) | (180.26M) | (30.03M) | (11.33M) |
| Free Cash Flow | 264.35M | 217.38M | 73.09M | 24.96M | (45.25M) |
Integra LifeSciences Holdings Corporation
NASDAQ:IART
Intrinsic Alpha fair value
Locked
Current Price
$13.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.